Efficacy and safety of 1-2, dimethyl-3-hydroxypyrid-4-one (L1) as an oral iron chelator in patients of beta thalassaemia major with iron overload.
Twenty-four patients with beta thalassaemia major, aged 8-22 years (mean 15.3 +/- 8.1) were given 1-2, dimethyl-3-hydroxypyrid-4-one (L1) orally for a period of three months. The drug was given in the dose of 25 mg/Kg/day for the first week and gradually increased to 100 mg/Kg/day which was continued until 3 months. The mean urinary iron excretion was 5.73 +/- 3.648 mg/day on 25 mg/Kg/day of L1; 15.2 +/- 11.225 mg/day on 50 mg/Kg/day; 24.2 +/- 12.69 mg/day on 75 mg/Kg/day and 36.3 +/- 19.4 mg/day on 100 mg/Kg/day of L1. Serum ferritin estimated by ELISA before and 3 months after L1 therapy in 21 patients showed significant drop in levels, the mean drop being 964.3 +/- 844.4 (P less than 0.001). The only side-effects noted were transient gastrointestinal symptoms in 5 patients and skeletomuscular pain in 3 patients. Both these groups of symptoms were of transient nature. The efficacy of L1 appears to be excellent and equivalent to the standard iron chelation therapy available at present i.e. desferrioxamine. It appears to be free of major toxicity. L1 is also a specific chelator for iron as it does not deplete trace metals. L1 appears to be a cheap and effective oral alternative to desferrioxamine for treating iron overloading.
Agarwal
M B
MB
Department of Medicine and Pathology, LTMG Hospital, Bombay.
Gupte
S S
SS
Vasandani
D
D
Viswanathan
C
C
Puniyani
R R
RR
Ramanathan
J
J
Massil
D E
DE
Shah
S
S
Rajyadhyaksha
G C
GC
Bhave
A A
AA
D000293:Adolescent; D015913:Chelation Therapy; D000077543:Deferiprone; D006432:Hemochromatosis / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D007502:Iron Chelating Agents / Q000627:therapeutic use*; D011728:Pyridones / Q000627:therapeutic use*; D013789:Thalassemia / Q000628:therapy*; D065227:Transfusion Reaction
D007502:Iron Chelating Agents; D011728:Pyridones; D000077543:Deferiprone